Corey Goodman marshals $105M mega-round for his CD47 upstart, looking to break new ground in PhII
Corey Goodman has put another notch on his venture belt, ringing up a $105 million mega-round for his CD47 startup ALX Oncology.
Fueling a startup backed by his group at venBIO, the new money will go to a slate of mid-stage studies to test the theory that his biotech’s ALX 148 could be a game-changer in the CD47 arena. And that could be nice window dressing for a company that may be looking to go the IPO route.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 144,300+ biopharma pros reading Endpoints daily — and it's free.